Study #2023-1019
Multicohort study to customize Ibrutinib treatment regimens for patients with previously untreated chronic lymphocytic leukemia
MD Anderson Study Status
Enrolling
Treatment Agent
Ibrutinib, Venetoclax
Description
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse events (AEs).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma
Study phase:
Phase II
Physician name:
Jan Burger
Department:
Leukemia
For general questions about clinical trials:
1-855-479-2433
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.